Assertio Holdings inc (ASRT) |
|
Price: $1.1200
$0.03
2.752%
|
Day's High:
| $1.12
| Week Perf:
| 19.82 %
|
Day's Low: |
$ 1.06 |
30 Day Perf: |
38.48 % |
Volume (M): |
1,833 |
52 Wk High: |
$ 8.01 |
Volume (M$): |
$ 2,053 |
52 Wk Avg: |
$3.36 |
Open: |
$1.08 |
52 Wk Low: |
$0.77 |
|
|
Market Capitalization (Millions $) |
80 |
Shares
Outstanding (Millions) |
71 |
Employees |
300 |
Revenues (TTM) (Millions $) |
152 |
Net Income (TTM) (Millions $) |
-332 |
Cash Flow (TTM) (Millions $) |
9 |
Capital Exp. (TTM) (Millions $) |
1 |
Assertio Holdings Inc
Assertio Holdings Inc. remains committed to delivering high-quality products and to meeting the needs of its customers.
In summary, Assertio Holdings Inc. is a specialty pharmaceutical company that develops and markets drugs for the treatment of various diseases. The company has a strong focus on quality control and regulatory adherence, and is committed to bringing new and innovative products to market. Despite facing some challenges in recent years, the company remains a leader in the pharmaceutical industry and is poised for future growth and success.
Company Address: 100 South Saunders Road Lake Forest 60045 IL
Company Phone Number: 419?7106 Stock Exchange / Ticker: NASDAQ ASRT
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Assertio Holdings Inc
Assertio Holdings Inc, a specialty pharmaceutical company, recently released its financial results for the October to December 31, 2023 interval. These results reveal a challenging period for the company, with diminishing returns, a significant decline in revenue, and a net deficit. However, despite these setbacks, Assertio remains committed to its growth strategy, focused on addressing unmet medical needs and providing patient-centric solutions. 1. Diminishing Returns and Improved EPS: In the October to December 31, 2023 interval, Assertio experienced a widening of diminishing returns by $-0.54 per share compared to the previous year. However, there is a glimmer of hope as the earnings per share (EPS) showed improvement, with a decrease from $-3.42 per share in the previous reporting period to $-4.67 per share.
|
Contract
Published Fri, Jan 5 2024 11:56 PM UTC
Assertio Holdings, Inc. (NASDAQ: ASRT), a prominent specialty pharmaceutical company, recently disclosed inducement grants awarded to two newly-hired employees. The Compensation Committee of the Company's Board of Directors approved the issuance of 16,498 restricted stock units (RSUs) and 18,654 stock options (options) effective January 2, 2024. This development solidifies A...
|
Assertio Holdings Inc
In its third quarter financial report for 2023, Assertio Holdings Inc revealed a significant shortfall per share of $-3.42, compared to $0.08 in the same period the previous year. However, revenue increased by 4.136%, reaching $35.63 million, compared to the corresponding reporting period a year ago. It is important to note that in the preceding reporting period, Assertio reported revenue of $40.99 million and a bottom line of $0.13 per share. In the third quarter of 2023, the company experienced a net shortfall of $-279.544 million, instead of the bottom line of $4.174 million achieved in the same period the previous year. One noticeable trend in Assertio's financial report is a significant buildup in inventories. The level of inventories and supplies increased to $42.7 million, higher than the preceding quarter as well as the corresponding quarter a year ago. This may indicate that the company is stockpiling products in anticipation of rising demand.
|
Assertio Holdings Inc
The financial period ending June 30, 2023, has brought forth interesting developments for Assertio Holdings Inc. This article aims to delve into the company's earnings report, uncovering notable trends and figures that highlight its performance within the stock market. Revenue Growth and Income Decline: In the fiscal period under review, Assertio Holdings Inc saw a noteworthy increase in revenue, rising by an impressive 16.68% to $40.99 million. However, this growth was countered by a decrease in income, which dwindled by 18.75% to $0.13 per share. Despite the revenue advance, this decline raises some concerns for investors.
|
Assertio Holdings Inc
Investors, it's time to take notice! Assertio Holdings Inc may have experienced a slip in earnings during the first quarter of 2023, but it is not all doom and gloom. Despite posting a loss of $-0.07 per share as opposed to $0.20 per share a year ago, Assertio Holdings Inc saw its revenue grow by an impressive 16.224%, hitting $42.47 million. While sequentially revenue fell by -15.663% from $50.35 million, let's not forget that the revenue growth signifies that the company is still on an upward trajectory. With the earnings season now behind us, it is understandable to be concerned about the future of the stock market. However, there is no need to worry about Assertio Holdings Inc. Yes, the company logged a net loss of $-3.484 million, but it returned a ROE of 52.5% in the first quarter of 2023. This is substantially larger than the company's average return on equity of -20.67%. While its ROE fell relative to the period ending, due to the decline in net income, it still outperformed the larger market.
|
Per Share |
Current |
Earnings (TTM) |
-3.9 $ |
Revenues (TTM) |
2.14 $
|
Cash Flow (TTM) |
0.12 $ |
Cash |
1.03 $
|
Book Value |
1.94 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-3.9 $
|
Revenues (TTM) |
2.14 $ |
Cash Flow (TTM) |
0.12 $ |
Cash |
1.03 $
|
Book Value |
1.94 $ |
Dividend (TTM) |
0 $ |
|
|
|
|